Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | TSPO | P30536 | 5/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5173620 | 0.89 | MLYCD (0.39) | HTR3ACNR2 | |
| SCHEMBL13848580 | 0.86 | CFD (0.38) | CNR2CNR1 | |
| SCHEMBL4011371 | 0.85 | CFD (0.40) | HTR3ACNR2TSPO | |
| SCHEMBL4019677 | 0.83 | TSPO (0.38) | TSPO | |
| SCHEMBL4013466 | 0.82 | MLYCD (0.38) | HTR3ACNR2NPC1 | |
| SCHEMBL4014319 | 0.82 | CFD (0.37) | HTR3ACNR2TSPO | |
| SCHEMBL4015275 | 0.81 | CNR2 (0.39) | CNR2NPC1RAB9A | |
| SCHEMBL4012522 | 0.80 | ATM (0.37) | HTR3ATSPO | |
| SCHEMBL4012899 | 0.80 | CNR2 (0.38) | CNR2NPC1RAB9A | |
| SCHEMBL3951267 | 0.78 | TSPO (0.38) | HTR3ATSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1581503-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060020000-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-01-26 | — | — | US | disclosed |
| EP-1581503-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004043354-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020000-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNJ11 | HTR3A 1931/4885CNR2 803/4885CNR1 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.